Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Vlaar et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00297-1
https://c19early.org/vlaar.html